Company: Gilead Sciences Inc

Check out which companies are making headlines after-the-bell Thursday:    Read More

Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek.    Read More

Earlier in the trading session, eBay shares were up as much as 16.6 percent, their best intraday gain since Oct. 2008.   Read More

Human Genome Sciences is one of the reasons the NYSE Arca Biotech Index is having its best day since December 2010.    Read More

The Spectrum Pharmaceuticals growth party is over.    Read More

Information technology and healthcare are two sectors where investors can find value, Peter Garnry, equity strategist at Saxo Bank told CNBC.   Read More

Six out of the 10 patients treated for hepatitis C with a combination of Gilead Science’s experimental drug GS-7977 relapsed, the company disclosed Friday. “This is just par for the course. There’s a reason people do trials on their drugs. You don't know what the answer is until you get the data,” said ISI analyst Mark Schoenebaum, who has a “buy” rating on Gilead.    Read More

Stocks in the S&P 1,500 that displayed unusual volume in Friday's trading session.   Read More

Cramer makes the call on viewers' favorite stocks.   Read More

Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!   Read More